careCycle vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 39)
careCycle logo

careCycle

EmergingHealthcare

Care Coordination & Transitions

careCycle is a healthcare platform that helps patients navigate post-acute care transitions — discharge planning, home health coordination, and care management after hospital stays. HQ: San Francisco.

AI VisibilityBeta
Overall Score
D39
Category Rank
#412 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
42
Perplexity
37
Gemini
42

About

careCycle is a care transition and post-acute care management platform designed to improve patient outcomes and reduce readmissions following hospital discharge. The company's technology helps care coordinators, discharge planners, and case managers navigate the complex process of transitioning patients from hospital to the next level of care — home health agencies, skilled nursing facilities, rehabilitation centers, or structured home care programs. Post-discharge coordination failures are a major driver of hospital readmissions, which cost the U.S. healthcare system approximately $26 billion annually.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

39
Overall Score
81
#412
Category Rank
#17
83
AI Consensus
71
stable
Trend
stable
42
ChatGPT
80
37
Perplexity
75
42
Gemini
77
44
Claude
86
39
Grok
85

Key Details

Category
Care Coordination & Transitions
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only careCycle
Care Coordination & Transitions

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.